Insider Trades16 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Buy | CVRX | Brent Binkowski | CHIEF OPERATING OFFICER | 26,223 | $2.91 | $76.7M | -74.51% | +30.91% | $76.4K | +86.57% | — | Stalk |
| Aug 12, 2026 | Sell | CVRX | Brent Binkowski | CHIEF OPERATING OFFICER | 1,309 | $2.55 | $76.7M | -74.51% | +30.91% | $3.3K | -4.14% | — | Stalk |
| Mar 2, 2026 | Sell | CVRX | Philip B. Adamson | Chief Medical Officer | 1,262 | $7.90 | $76.7M | -74.51% | +30.91% | $10.0K | -1.01% | — | Stalk |
| Mar 2, 2026 | Sell | CVRX | Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 1,284 | $7.90 | $76.7M | -74.51% | +30.91% | $10.1K | -1.00% | — | Stalk |
| Mar 2, 2026 | Sell | CVRX | Jared Oasheim | CHIEF FINANCIAL OFFICER | 1,744 | $7.90 | $76.7M | -74.51% | +30.91% | $13.8K | -0.92% | — | Stalk |
| Mar 2, 2026 | Sell | CVRX | Robert Allen John | Chief Revenue Officer | 3,964 | $7.90 | $76.7M | -74.51% | +30.91% | $31.3K | -2.79% | — | Stalk |
| Mar 2, 2026 | Sell | CVRX | Kevin Hykes | PRES & CEO | 7,763 | $7.90 | $76.7M | -74.51% | +30.91% | $61.3K | -1.46% | — | Stalk |
| May 12, 2025 | Buy | CVRX | Kevin Hykes | PRES & CEO | 5,000 | $4.84 | $76.7M | -74.51% | +30.91% | $24.2K | +3.91% | — | Stalk |
| Nov 19, 2024 | Buy | CVRX | Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 4,970 | $6.49 | $76.7M | -74.51% | +30.91% | $32.3K | +0.04% | — | Stalk |
| Aug 5, 2024 | Buy | CVRX | Kevin Hykes | PRES & CEO | 30,000 | $8.36 | $76.7M | -74.51% | +30.91% | $250.8K | — | — | Stalk |
| Mar 25, 2024 | Buy | CVRX | Craig E. Palmer | SVP, U.S. SALES | 934 | $0.24 | $76.7M | -74.51% | +30.91% | $221.358 | +45.63% | — | Stalk |
| Feb 23, 2024 | Sell | CVRX | Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 1,650 | $22.21 | $76.7M | -74.51% | +30.91% | $36.6K | -67.21% | — | Stalk |
| Feb 20, 2024 | Buy | CVRX | Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 7,545 | $10.80 | $76.7M | -74.51% | +30.91% | $81.5K | +3.04% | — | Stalk |
| Jan 29, 2024 | Buy | CVRX | Nadim Yared | CHIEF EXECUTIVE OFFICER | 6,000 | $0.24 | $76.7M | -74.51% | +30.91% | $1.4K | +8.15% | — | Stalk |
| Oct 16, 2023 | Buy | CVRX | Liz Galle | VP OF GLOBAL CLINICAL RESEARCH | 778 | $0.24 | $76.7M | -74.51% | +30.91% | $184.386 | — | — | Stalk |
| Sep 18, 2023 | Buy | CVRX | Jared Oasheim | CHIEF FINANCIAL OFFICER | 5,862 | $3.62 | $76.7M | -74.51% | +30.91% | $21.2K | +18.65% | — | Stalk |